COSCIENS Biopharma Inc T.CSCI

Diclofenac

[prophetoffactz]

One drug that Gilles said they were trying to incorporate into a PGX carrier is diclofenac. That was said some time ago and we never heard anything since. 

Diclofenac is one of the most widely used nonsteroidal anti-inflammatory drugs (NSAIDs) globally. Here are some key points about its popularity and market size:

Popularity

Diclofenac is extremely popular worldwide, particularly outside the United States:

• It is the most widely prescribed NSAID globally.
• In 2022, it was the 51st most commonly prescribed medication in the United States, with over 12 million prescriptions.
• As of 2013, it was described as "by far the most widely used non-steroidal anti-inflammatory drug" worldwide.

Market Size and Forecasts

The diclofenac market is substantial and growing:

• The global diclofenac market size is projected to reach $6.1 billion by 2027.
• It is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% over the forecast period.

Regional Trends

• North America is anticipated to gain a significant market share in the diclofenac market during the forecast period.
• The market growth in North America is driven by factors such as the growing prevalence of arthritis, robust medical infrastructure, and increasing regulatory approvals for diclofenac medications.

Product Segments

• The oral segment accounted for a significant proportion of the diclofenac market in 2023, attributed to increasing regulatory approvals and the launch of new oral diclofenac generics.
• The parenteral and topical segments are also expected to show considerable growth.

While specific annual revenue figures for diclofenac alone are not provided in the search results, it's clear that diclofenac represents a significant and growing segment of the global analgesics market. The overall analgesics market, which includes diclofenac, is projected to generate revenues of $33.05 billion worldwide in 2024, with an expected annual growth rate of 6.49%.

Share

Rewrite

Based on the research presented, there is potential for combining diclofenac with Ceapro's PGX-processed yeast beta glucan (PGX-YBG) for wound healing and potentially treating fibrotic conditions. While the study does not directly mention skin cancer treatment, the findings suggest promising applications for wound healing and fibrosis-related conditions.

Wound Healing Potential

PGX-YBG microparticles have shown significant potential for wound healing applications:

• PGX-YBG activates the Dectin-1 receptor more efficiently in vitro compared to commercially available spray-dried YBGs.
• The microparticles effectively modulate pro-fibrotic M2-like macrophages into fibrosis-suppressing macrophages, both in vitro and in ex vivo precision-cut murine lung slices.
• PGX-YBG has higher surface areas, lower densities, and smaller, more uniform size distributions compared to conventional YBGs, potentially enhancing its therapeutic effects.

Fibrotic Conditions

The research suggests that PGX-YBG could be beneficial in treating fibrotic conditions:

• PGX-YBG can reprogram pro-fibrotic macrophages, which are implicated in the pathogenesis and progression of lung fibrosis.
• The microparticles show potential utility in addressing a broad spectrum of fibrotic end-point lung diseases.
• PGX-YBG was found to be safe and well-tolerated in both nave and fibrotic mice, with no lung injury or vessel damage observed.

Potential Synergy with Diclofenac

While the study does not specifically mention combining PGX-YBG with diclofenac, there may be potential benefits in doing so:

• Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that could complement the immunomodulatory effects of PGX-YBG.
• The anti-inflammatory properties of diclofenac might enhance the wound healing and anti-fibrotic effects of PGX-YBG.

Other Potential Applications

Based on the research, combining diclofenac with PGX-YBG might also be beneficial for:

1. Chronic wound management
2. Inflammatory skin conditions
3. Diabetic foot ulcers
4. Burn wound healing

It's important to note that further research would be needed to fully evaluate the potential synergistic effects of combining diclofenac with PGX-YBG for these applications.